{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:16:48Z","timestamp":1792793808477,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T00:00:00Z","timestamp":1641340800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.cgh.2021.12.044","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T12:19:58Z","timestamp":1641471598000},"page":"143-152.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor\/Firsocostat"],"prefix":"10.1016","volume":"21","author":[{"given":"Eric J.","family":"Lawitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal Raj","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Ruane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Kohli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza","family":"Harting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Chieh","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan S.","family":"Huss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuhan","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2021.12.044_bib1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.12.044_bib2","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1053\/j.gastro.2017.01.003","article-title":"Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation","volume":"152","author":"Goldberg","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2021.12.044_bib3","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.cgh.2021.12.044_bib4","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/hep.23719","article-title":"Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites","volume":"52","author":"Neuschwander-Tetri","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.12.044_bib5","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1136\/gutjnl-2019-319104","article-title":"Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges","volume":"69","author":"Dufour","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2021.12.044_bib6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jcmgh.2019.04.007","article-title":"Metabolic targets in nonalcoholic fatty liver disease","volume":"8","author":"Esler","year":"2019","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.12.044_bib7","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"ATLAS Investigators. Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.12.044_bib8","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1002\/hep.30097","article-title":"Acetyl-CoA carboxylase inhibition reverses NAFLD and hepatic insulin resistance but promotes hypertriglyceridemia in rodents","volume":"68","author":"Goedeke","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.12.044_bib9","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.cgh.2018.04.042","article-title":"Acetyl-CoA carboxylase inhibitor GS-0976 for 12 weeks reduces hepatic de novo lipogenesis and steatosis in patients with nonalcoholic steatohepatitis","volume":"16","author":"Lawitz","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.12.044_bib10","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1053\/j.gastro.2018.07.027","article-title":"GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease","volume":"155","author":"Loomba","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2021.12.044_bib11","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.cmet.2017.07.009","article-title":"Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: a bedside to bench investigation","volume":"26","author":"Kim","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.cgh.2021.12.044_bib12","doi-asserted-by":"crossref","first-page":"10918","DOI":"10.1074\/jbc.275.15.10918","article-title":"Farnesoid X receptor responds to bile acids and represses cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription","volume":"275","author":"Chiang","year":"2000","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.cgh.2021.12.044_bib13","doi-asserted-by":"crossref","first-page":"G349","DOI":"10.1152\/ajpgi.00417.2002","article-title":"Bile acid regulation of hepatic physiology: III. Bile acids and nuclear receptors","volume":"284","author":"Chiang","year":"2003","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.cgh.2021.12.044_bib14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.mce.2012.05.004","article-title":"FXR signaling in the enterohepatic system","volume":"368","author":"Matsubara","year":"2013","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.cgh.2021.12.044_bib15","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/hep.29359","article-title":"The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids","volume":"67","author":"Puri","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.12.044_bib16","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1172\/JCI21025","article-title":"Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c","volume":"113","author":"Watanabe","year":"2004","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.cgh.2021.12.044_bib17","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3748\/wjg.v20.i7.1724","article-title":"Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease","volume":"20","author":"Ballestri","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2021.12.044_bib18","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/aje\/kws448","article-title":"Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994","volume":"178","author":"Lazo","year":"2013","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.cgh.2021.12.044_bib19","first-page":"LP5","article-title":"Fenofibrate mitigates increases in serum triglycerides due to the ACC inhibitor firsocostat in patients with advanced fibrosis due to NASH (abstract)","volume":"70","author":"Lawitz","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.12.044_bib20","doi-asserted-by":"crossref","unstructured":"United States Department of Health and Human Services. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). National Institutes of Health Publication No. 01-3670; May\u00a02001.","DOI":"10.1001\/jama.285.19.2486"},{"key":"10.1016\/j.cgh.2021.12.044_bib21","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/liv.14871","article-title":"Safety of fibrates in cholestatic liver diseases","volume":"41","author":"Carrion","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2021.12.044_bib22","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A\u00a0placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2021.12.044_bib23","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2021.12.044_bib24","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.14209","article-title":"CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients","volume":"39","author":"Pockros","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2021.12.044_bib25","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jhep.2018.11.032","article-title":"Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis","volume":"70","author":"Rinella","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2021.12.044_bib26","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"GOLDEN-505 Investigator Study Group. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"issue":"Suppl","key":"10.1016\/j.cgh.2021.12.044_bib27","first-page":"9A","article-title":"The PANPPAR agonist lanifibranor induces both resolution of NASH and regression of fibrosis after 24 weeks of treatment in non-cirrhotic NASH: results of the native phase 2b trial","volume":"72","author":"Francque","year":"2020","journal-title":"Hepatology"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356522000027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356522000027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:40:40Z","timestamp":1761543640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356522000027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1542356522000027"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2021.12.044","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor\/Firsocostat","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2021.12.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the AGA Institute. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}